Adverum Biotechnologies provides update on the INFINITY trial evaluating ADVM 022 in patients with diabetic macular edema.
Related news and insights
Regeneron Pharmaceuticals, Inc. announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)
Alimera Sciences announced that the PALADIN Phase IV Study confirms the safety of Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients with diabetic macular oedema (DME)
Roche has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Vabysmo (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and visual impairment due to diabetic macular edema (DME).